Literature DB >> 22068432

Controversy over the classification of medication-overuse headache.

Maurice B Vincent1.   

Abstract

Medication-overuse headache (MOH) is a relatively common and impactful disorder, affecting 1% to 2% of the population, characterized by daily or near-daily headache aggravated by chronic acute medication intake. Primary headache patients do not necessarily develop MOH after acute medication overuse, although a pre-existing primary headache is inevitably present. Likewise, headache patients may deteriorate in terms of frequency without medication overuse, or suffer from chronic headache in the presence of drug abuse without any causal relationship. To classify and define diagnostic criteria for MOH in the absence of objective biomarkers is a difficult task that is presently based on clinical grounds and is limited in part by the relative lack of research in this field. The present criteria are less restrictive but also less precise than the previous versions because they allow the diagnosis without the previously required MOH confirmation after medication withdrawal. MOH should remain as a distinct secondary disorder based on the available clinical and pathophysiological evidence.

Entities:  

Mesh:

Year:  2012        PMID: 22068432     DOI: 10.1007/s11916-011-0229-8

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  31 in total

1.  Medication overuse headache: type I and type II.

Authors:  J R Saper; A E Lake
Journal:  Cephalalgia       Date:  2006-10       Impact factor: 6.292

Review 2.  Risk factors for headache chronification.

Authors:  Ann I Scher; Lynn A Midgette; Richard B Lipton
Journal:  Headache       Date:  2008-01       Impact factor: 5.887

3.  New appendix criteria open for a broader concept of chronic migraine.

Authors:  J Olesen; M-G Bousser; H-C Diener; D Dodick; M First; P J Goadsby; H Göbel; M J A Lainez; J W Lance; R B Lipton; G Nappi; F Sakai; J Schoenen; S D Silberstein; T J Steiner
Journal:  Cephalalgia       Date:  2006-06       Impact factor: 6.292

4.  Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures.

Authors:  I Ayzenberg; M Obermann; P Nyhuis; M Gastpar; V Limmroth; H C Diener; H Kaube; Z Katsarava
Journal:  Cephalalgia       Date:  2006-09       Impact factor: 6.292

5.  A genetic association study of dopamine metabolism-related genes and chronic headache with drug abuse.

Authors:  S Cevoli; M Mochi; C Scapoli; N Marzocchi; G Pierangeli; L A Pini; P Cortelli; P Montagna
Journal:  Eur J Neurol       Date:  2006-09       Impact factor: 6.089

6.  Epidemiology of medication overuse headache in the general Swedish population.

Authors:  Pernilla Jonsson; Tove Hedenrud; Mattias Linde
Journal:  Cephalalgia       Date:  2011-05-31       Impact factor: 6.292

7.  Headache characteristics and chronification of migraine and tension-type headache: A population-based study.

Authors:  Sait Ashina; Ann Lyngberg; Rigmor Jensen
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

Review 8.  Past, present, and future prospects of medication-overuse headache classification.

Authors:  Anna Ferrari; Ciro Coccia; Emilio Sternieri
Journal:  Headache       Date:  2008-07       Impact factor: 5.887

9.  Family history for chronic headache and drug overuse as a risk factor for headache chronification.

Authors:  Sabina Cevoli; Elisa Sancisi; Daniela Grimaldi; Giulia Pierangeli; Stefano Zanigni; Marianna Nicodemo; Pietro Cortelli; Pasquale Montagna
Journal:  Headache       Date:  2009-03       Impact factor: 5.887

10.  Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes.

Authors:  M E Bigal; A M Rapoport; F D Sheftell; S J Tepper; R B Lipton
Journal:  Cephalalgia       Date:  2004-06       Impact factor: 6.292

View more
  1 in total

Review 1.  Pharmacotherapy for Persistent Posttraumatic Headaches in Children and Adolescents: A Brief Review of the Literature.

Authors:  Joanne Kacperski
Journal:  Paediatr Drugs       Date:  2018-10       Impact factor: 3.022

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.